An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer

Nature Biotechnology

Volumn 27, Issue 11, 2009, Pages 1005-1011

  Wang, Xiao Song ^a,b,c   Prensner, John R ^a,c   Chen, Guoan ^c   Cao, Qi ^a,c   Han, Bo ^a,c   Dhanasekaran, Saravana M ^a,c   Ponnala, Rakesh ^a   Cao, Xuhong ^a,c   Varambally, Sooryanarayana ^a,c   Thomas, Dafydd G ^c   Giordano, Thomas J ^c   Beer, David G ^c   Palanisamy, Nallasivam ^a,c   Sartor, Maureen A ^b   Omenn, Gilbert S ^b   Chinnaiyan, Arul M ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b CCMB   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT; CANCER GENES; CANCER GENOME; CELL LINES; COPY NUMBER; FUNCTIONAL ANNOTATION; FUSION PARTNERS; GENE FUSION; GENOMIC DATA; HIGH-THROUGHPUT DATA; KEY CHARACTERISTICS; LUNG CANCER; LUNG TISSUE; SYSTEMATIC ANALYSIS; TRANSCRIPTOMES;

ASSOCIATION REACTIONS; BIOLOGICAL ORGANS; CELL CULTURE;

GENES;

HYBRID PROTEIN; PROTEIN NFE2; PROTEIN R3HDM2; UNCLASSIFIED DRUG;

ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE FUSION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; HUMAN CELL; LUNG CANCER; LUNG PARENCHYMA; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE;

ALGORITHMS; ANIMALS; COMPUTATIONAL BIOLOGY; GENE FUSION; GENES, NEOPLASM; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; POINT MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECOMBINATION, GENETIC; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA;

EID: 70449375354     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1584     Document Type: Article

References (31)

1. Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233-245 (2007).
2. Tomlins, S.A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
3. Soda, M. et al. Identifcation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
4. Kumar-Sinha, C., Tomlins, S.A. & Chinnaiyan, A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497-511 (2008).
5. Vastrik, I. et al. Reactome: a knowledge base of biologic pathways and processes. Genome Biol. 8, R39 (2007).
6. Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y. & Hattori, M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 32, D277-280 (2004).
7. Prasad, T.S. et al. Human Protein Reference Database-2009 update. Nucleic Acids Res. 37, D767-72 (2009).
8. Hu, Z. et al. VisANT 3.0: new modules for pathway visualization, editing, prediction and construction. Nucleic Acids Res. 35, W625-632 (2007).
9. Chen, C. et al. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr. Relat. Cancer 14, 513-529 (2007).
10. Chen, G.J., Weylie, B., Hu, C., Zhu, J. & Forough, R. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470). J. Cell. Biochem. 101, 1492-1504 (2007).
11. Vantler, M. et al. PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases. FEBS Lett. 580, 6769-6776 (2006).
12. Walz, C., Cross, N.C., Van Etten, R.A. & Reiter, A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22, 1320-1334 (2008).
13. Fuhrer, D.K. & Yang, Y.C. Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11. Biochem. Biophys. Res. Commun. 224, 289-296 (1996).
14. Kharas, M.G. et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118, 3038-3050 (2008).
15. Mullighan, C.G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110-114 (2008).
16. Mullighan, C.G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).
17. Drexler, H.G.. The Leukemia-Lymphoma Cell Line Factsbook (Academic Press, San Diego, 2000).
18. Mitelman, F., Mertens, F. & Johansson, B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat. Genet. 15 Spec No 417-474 (1997).
19. Maher, C.A. et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl. Acad. Sci. USA 106, 12353-12358 (2009).
20. Bashir, A., Volik, S., Collins, C., Bafna, V. & Raphael, B.J. Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. PLoS Comput. Biol. 4, e1000051 (2008).
21. Kent, W.J. BLAT-the BLAST-like alignment tool. Genome Res. 12, 656-664 (2002).
22. Wishart, D.S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-D672 (2006).
23. Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004).
24. Weir, B.A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
25. Richard, W. Overall experiment characteristics. National Cancer Institute
26. https://array.nci.nih.gov/caarray/project/woost-00041? (2009).
27. Roth, R.B. et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 7, 67-80 (2006).
28. Rhodes, D.R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profles. Neoplasia 9, 166-180 (2007).
29. Rubin, M.A. et al. Overexpression, amplifcation, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 64, 3814-3822 (2004).
30. Garraway, L.A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplifed in malignant melanoma. Nature 436, 117-122 (2005).
31. Cao, Q. et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274-7284 (2008)